Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown

MT Newswires Live07-08

Aerovate Therapeutics (AVTE) said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial and the long-term extension study.

The company said it sought the assistance of Wedbush PacGrow in the process of exploring alternatives, which may include an acquisition, merger, reverse merger, business combination, liquidation, or other transaction.

There is no timetable for completion of the review process and there is no assurance that the process will lead to a deal, the company said.

Shares of Aerovate Therapeutics were up 3.1% in premarket activity.

Price: 1.6500, Change: +0.04, Percent Change: +2.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2449777987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-08 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449777987","market":"nz","top_or_hot":-1,"title":"Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown","media":"MT Newswires Live","content":"<html><body><p> Aerovate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AVTE) said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial and the long-term extension study.</p><p>The company said it sought the assistance of Wedbush PacGrow in the process of exploring alternatives, which may include an acquisition, merger, reverse merger, business combination, liquidation, or other transaction.</p><p>There is no timetable for completion of the review process and there is no assurance that the process will lead to a deal, the company said.</p><p>Shares of Aerovate Therapeutics were up 3.1% in premarket activity.</p><p>Price: 1.6500, Change: +0.04, Percent Change: +2.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-08 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aerovate Therapeutics (AVTE) said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2449777987","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449777987","pubTimestamp":1720442696,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aerovate Therapeutics  said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial and the long-term extension study.The company said it sought the assistance of Wedbush PacGrow in the process of exploring alternatives, which may include an acquisition, merger, reverse merger, business combination, liquidation, or other transaction.There is no timetable for completion of the review process and there is no assurance that the process will lead to a deal, the company said.Shares of Aerovate Therapeutics were up 3.1% in premarket activity.Price: 1.6500, Change: +0.04, Percent Change: +2.48","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","AVTE":"Aerovate Therapeutics, Inc."},"translate_title":"Aerovate Therapeutics将在高血压试验停止后探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTE":1,"LENZ":1},"content_text":"Aerovate Therapeutics (AVTE) said Monday it will consider strategic alternatives following its announcement that it was stopping enrollment and shutting down the phase 3 portion of its Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial and the long-term extension study.The company said it sought the assistance of Wedbush PacGrow in the process of exploring alternatives, which may include an acquisition, merger, reverse merger, business combination, liquidation, or other transaction.There is no timetable for completion of the review process and there is no assurance that the process will lead to a deal, the company said.Shares of Aerovate Therapeutics were up 3.1% in premarket activity.Price: 1.6500, Change: +0.04, Percent Change: +2.48","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449777987"}